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Abstract

Objectives Non-surgical contraceptive management of free-roaming cat populations is a global goal for public
health and humane reasons. The objectives of this study were to measure the duration of contraception following
a single intramuscular injection of a gonadotropin-releasing hormone-based vaccine (GonaCon) and to confirm its
safe use in female cats living in colony conditions.
Methods GonaCon (0.5 ml/cat) was administered intramuscularly to 20 intact female cats (queens), and saline was
administered to 10 queens serving as sham-treated controls. Beginning in late February, 4 months after injection,
all cats were housed with fertile male cats in a simulated colony environment. Time to pregnancy, fetal counts and
vaccine-elicited injection-site reactions were evaluated.
Results All control cats (n = 10/10) and 60% (n = 12/20) of vaccinated cats became pregnant within 4 months of
the introduction of males. Two additional vaccinates became pregnant (70%; n = 14/20) within 1 year of treatment.
Average fetal counts were significantly lower in vaccinated cats than in control cats. Vaccinates had a significantly
longer (P = 0.0120) median time to conception (212 days) compared with controls (127.5 days). Injection-site
reactions ranging from swelling to transient granulomatous masses were observed in 45% (n = 9/20) of vaccinated
cats.
Conclusions and relevance A single dose of GonaCon provided contraception lasting for a minimum of 1 year in
30% (n = 6/20) of treated cats. The level of contraception induced by this GonaCon dose and vaccine lot was not
sufficiently effective to be recommended for use in free-roaming cats.
Accepted: 17 January 2018
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Introduction
Control of free-roaming cat (FRC) populations is desired
by multiple stakeholders to improve the welfare of cats,
other species and society. While surgical sterilization
serves as the cornerstone of humane FRC management,
long-acting non-surgical contraceptive methods are
being explored as potential cost-effective adjuncts to
surgery. GonaCon, a gonadotropin-releasing hormone
(GnRH) vaccine developed by the US Department of
Agriculture, Animal and Plant Health Inspection Service
(USDA APHIS), Wildlife Services’ National Wildlife
Research Center (NWRC), is one such approach.
GonaCon Immunocontraceptive Vaccine and GonaConEquine are registered by the US Environmental
Protection Agency (EPA) for contraception of adult
female white-tailed deer, and wild horses and burros,
respectively. GonaCon has undergone several formulation changes since its initial development by the NWRC,
and the name has been loosely applied in the literature
to different formulations. All GonaCon formulations
have included a carrier protein presenting multiple copies of a GnRH peptide, emulsified in a mineral oil-based
mycobacterium-containing adjuvant.
Levy et al were the first to demonstrate safety and
efficacy of a previous formulation of the GnRH vaccine
in the laboratory using commercial, vendor-acquired,
specific-pathogen-free female cats.1 Fifteen adult queens
were injected intramuscularly with 0.5 ml of this GnRH
vaccine, and five control cats were injected with a sham
vaccine. In a 5 year breeding trial starting 120 days postvaccination, vaccinated cats had a significantly longer
median time to conception (39.7 months) compared with
sham-treated cats (4.4 months). Granulomatous injection-
site masses appeared 2 years after vaccination in 33%
(n = 5/15) of treated cats. Stochastic modeling suggested
that this median duration of infertility could position an
injectable contraceptive to rival permanent sterilization
of cats for short-term population reduction in the first 5
years of use, though it would be less effective over the
longer term of 10 years.2
Owing to changes in vaccine formulation following
the Levy et al study,1 plus consideration of the potential
for injection-site reactions, a short-term safety study
using the current formulation of GonaCon was conducted in six adult spayed female purpose-bred cats at
the Cincinnati Zoo’s Center for Conservation and
Research of Endangered Wildlife.3 GnRH antibodies
developed within 30 days in all vaccinates and persisted
throughout the 4 month study. Although transient injection-site reactions were observed in 66% (n = 4/6) of
cats, the levels of safety and immunogenicity demonstrated were deemed adequate for further evaluation.
The purpose of the current study was to determine
the duration of immunocontraception induced by vaccination with 0.5 ml GonaCon in a diverse group of queens
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living under conditions that closely resembled a FRC
population. It was hypothesized that GonaCon administration would result in prolonged and safe contraception
of female cats under simulated FRC colony conditions.
The design of the current study, when compared with
the Levy et al study in female laboratory cats,1 modified
both the source of animals and their housing conditions.
Specific study objectives were to measure duration of
contraception following a single intramuscular injection
of GonaCon and to confirm the clinical safety of a single
injection of GonaCon.

Materials and methods
Animals and environment
Forty-five cats (38 females, seven males) were screened
for potential participation in the study. All were domestic
short- or medium-hair cats, with estimated ages ranging
from 4 months to 3 years (females) and 1–3 years (males)
at the time of screening. Forty cats (33 females, seven
males) were acquired from four animal control agencies
in four non-adjacent Illinois counties; efforts were made
to select cats at high risk of euthanasia. Four cats were
acquired from private individuals who posted cats for
rehoming on a classified advertisement website, and one
from a feline rescue. Six sister pairs were enrolled; beyond
those sibling relationships, it is expected that the study
population was genetically diverse owing to geographic
distribution of cat sources. Cats that were screened but
not enrolled in the study were surgically sterilized and
adopted into private homes.
The study was performed at Clowder Concepts, a
USDA-registered Class R research facility, and all procedures were approved by the facility’s Institutional
Animal Care and Use Committee. The facility was
located in a rural community outside of UrbanaChampaign, IL, USA, and was licensed and inspected by
the Illinois Department of Agriculture as an animal shelter. Cats were group housed in a 1400-square-foot room
with a loft and ample opportunities to perch, climb and
hide. The room was maintained at ambient temperatures
between 20ºC and 27°C. Cats had access during daylight
hours to an outdoor fenced enclosure (one-third of an
acre) with grasses, shrubs and trees. Light provided
inside the facility was adjusted to reflect the natural
photoperiod. Cats were fed a commercial dry cat food
with access to fresh water ad libitum; canned food and
treats were provided for enrichment.
Intake and screening procedures
Female cats Prior to entering the facility, each female cat
underwent a physical examination to rule out pregnancy,
clinical signs of illness and behaviors incompatible with
group housing or low-stress handling. Preventive healthcare was provided as described in Table 1. Cats were
visually assessed twice daily for general wellbeing and
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Table 1 Cat intake and conditioning procedures
Complete physical examination (repeated within 3–4 weeks)
Scanned for presence of microchip
Wood’s lamp examination for ringworm
Vaccination against feline viral rhinotracheitis, calicivirus, panleukopenia/feline leukemia virus (FeLV) (repeated within 3–4
weeks)
Treatment with imidacloprid/moxidectin and praziquantel
Complete blood count and serum chemistry panel
FeLV antigen and feline immunodeficiency virus antibody test*
Abdominal ultrasonographic examination for general health and pregnancy detection (repeated within 3–4 weeks)
Implantation of RFID microchip
Rabies vaccination
*Cats were individually housed until this test was performed and yielded a negative result. All females were retested on study day 0, which was
at least 30 days after the initial test
RFID = radio-frequency identification

received monthly physical examinations and monthly
treatment with imidacloprid plus moxidectin (Advantage Multi; Bayer) for the duration of the study.
Male cats Male cats were transferred to the facility a

minimum of 4 months after the females and underwent
the procedures described in Table 1, except for ultrasound examinations. Additionally, all males were
assessed for fertility. Semen was collected under sedation via urethral catheterization or electroejaculation.4,5
Immediately after collection, semen was subjected to a
standardized semen analysis.6
Study design
Thirty female cats were selected based on health and
behavior. To randomly assign treatment groups, cats
were listed from youngest to oldest based on estimated
age. A randomization table was generated assigning
each female cat to receive either GonaCon or sterile
saline (control group), starting with cat 1, in groups of
three (with two GonaCon and one control in each group).
This randomization resulted in 20 GonaCon-treated cats
and 10 control cats. With the exception of the veterinarian who administered the injections, the study statistician and the study monitor, all other study personnel
were blinded to each cat’s treatment assignment until
the cat was diagnosed as pregnant. Five male cats were
selected for use in the study based on health, behavior
and fertility.
Design and funding allowed for up to a 5 year study
duration, based on cat safety and vaccine effectiveness.
Lack of demonstration of vaccine effectiveness in the
first year led to the decision to terminate the study 1 year
post-vaccination. All cats were surgically sterilized and
adopted to private homes at the end of the study.
Vaccination
‘GonaCon’ refers to a formulation identical to the
GonaCon Immunocontraceptive Vaccine (EPA registration 56228-40) and GonaCon-Equine (EPA registration
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56228-41) products but applied in a smaller dose for this
unregistered, experimental use in domestic cats.
GonaCon was provided by the USDA/NWRC, Fort
Collins, CO, USA. Pre-filled syringe doses were shipped
in a cooler with ice packs to the test facility and kept
under refrigerated conditions until administration. The
vaccine was kept at a refrigerated temperature from
manufacture until use, as documented by chain of custody forms. In order to mimic field conditions, cats were
not sedated and the injection site was not prepared prior
to injection of 0.5 ml GonaCon or sterile saline into the
right quadriceps muscle group using an 18 G needle.
The day of vaccination was designated study day 0.
Safety observations
Injection sites were palpated daily for 1 week following
treatment, then weekly for 1 month and then at least
monthly. Cats were observed daily, and any adverse
events were recorded on adverse event forms. Baseline
serum chemistry and hematology analysis was performed prior to vaccination on each cat, and repeated on
day 34.
Breeding trial
The breeding trial began with the first male cat introduced 115 days after treatment. This date corresponded
with a period of increasing day length (late February)
and the time of year typically associated with the beginning of increased feline estrous activity. A rotation of five
breeding males mitigated effects of inter-cat behavioral
incompatibility on breeding success. All estrous behaviors and breeding attempts that occurred in the presence
of project personnel were recorded. Cats were not under
24 h observation, so it is likely that some estrous and
breeding behaviors went unobserved and unrecorded.
Pregnancy diagnosis and ovariohysterectomy
A veterinarian performed monthly ultrasonographic
examinations of each queen, beginning 1 month after initiation of the breeding trial. Cats identified as pregnant
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conceived and therefore 14 GonaCon-treated cats (70%)
had become pregnant. The GonaCon-vaccinated group
had a longer median time to conception following treatment (212 days) than controls (127.5 days; P = 0.01;
Figure 1). Litter size (mean ± SD) was significantly
smaller in the GonaCon-vaccinated group (3.9 ± 1.7)
compared with the control group (5.6 ± 1.8; P = 0.04)
(Table 2). There was one unviable (likely resorbed) fetus
detected in a vaccinate litter and one in a control litter.

Figure 1 Fertility control in cats. Vaccinated cats (n = 20)
received an intramuscular (IM) injection of GonaCon on
study day 0. Control cats (n = 10) received an IM injection
of saline. A breeding trial commenced on study day 115 and
terminated on day 363. Vaccinated cats had longer median
time to conception (212 days) than control cats (127.5 days;
P = 0.0120). Six vaccinated cats remained infertile for the
duration of the breeding trial

were ovariohysterectomized between 0 and 8 days after
pregnancy was confirmed, and always prior to an estimated day 45 of gestation.
Time to conception was defined as the interval between
day 0 and conception, which was estimated by measuring
fetal crown–rump length. The length of each fetus was
measured with calipers, and the median litter fetal crown–
rump length value was calculated for each litter. Fetal age
was estimated as per published guidelines.7 If the median
crown–rump length was <58 mm, the date of conception
was arbitrarily designated as 30 days prior to the spay
surgery. Fetuses were visually evaluated for normal
development, but necropsies were not performed.
Statistical analyses
Differences in the median time to conception between
the vaccinated and control groups were determined by
the Kaplan–Meier survival analysis log rank test. Mean
± SEM and median were calculated for litter size. Means
and medians were compared using the Student’s t-test
and Wilcoxon rank-sum test, respectively.

Results
Breeding trial
Time to pregnancy is shown in Figure 1. Six control cats
(60%) and eight GonaCon-treated cats (40%) displayed
behavioral signs of estrus and became pregnant within
the first month of the breeding trial. By the fourth month
of the breeding trial all control cats (n = 10) had become
pregnant, as had 12 (60%) of the GonaCon-treated cats.
At 1 year post-treatment, two additional queens had
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Estrous behaviors
Based on observations during working hours (typically
72 h per week and excluding overnight periods), estrous
behaviors were never observed in 4/6 vaccinated cats
that did not become pregnant. The other two vaccinates
exhibited estrous behaviors, even before the breeding
trial began, and then engaged in breeding multiple times
over the course of the study but did not conceive. The
last vaccinate that conceived (cat 25 on day 273) displayed persistent estrous behaviors and accepted the
males repeatedly for 5 months prior to conception.
Safety
There were a variety of adverse events that occurred
during the trial that would be expected in a colony of 30
co-housed female cats, plus a rotation of male cats.
However, there was no pattern to indicate that any
adverse events were related to treatment group, with the
exception of injection-site reactions.
Three vaccinates (cats 9, 21, 36) were observed limping on the right hindlimb beginning 3–7 h after treatment, which resolved within 24 h. No other acute
adverse reactions related to vaccination were observed.
Nearly half of the treated cats (n = 9/20) had a
delayed (beginning at least 1 month after treatment)
injection-site reaction in the region in which GonaCon
was administered. Seven of these cats developed soft
tissue masses near the site of injection at variable time
points, and mass size fluctuated over variable durations.
The other two cats developed swelling with no palpable
mass.
Reactions for six cats with delayed reactions resolved
within 2–3 months post-injection, whereas reactions for
three cats were detected during or after month 7 and persisted through their adoption and exit from the study.
Among these nine cats with delayed injection-site reactions, none demonstrated prolonged pain or difficulty
ambulating, and there was no evidence of ulceration or
other external irritation. A summary of injection-site
reactions is presented in Table 3.
Wedge biopsies were performed under general anesthesia on two of the later-onset masses (cats 8 and 18).
Histological evaluation indicated the lesions were granulomatous to pyogranulomatous panniculitis with
inter-lesional acid-fast bacteria. Aerobic, anaerobic and
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Table 2 Time to conception, injection-site reaction incidence and litter size in individual control cats (n = 10) and
GonaCon-treated cats (n = 20)
Treatment

Cat

Conception (day)

Injection-site reaction

Fetuses at spay

Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon
GonaCon

1
10
13
20
32
19
7
17
24
23
9
31
28
15
8
11
37
5
14
22
3
30
18
25
6
12
21
27
36
38

123
123
123
123
123
132
190
211
219
234
123
123
123
131
142
142
142
145
190
198
226
234
251
273
NA
NA
NA
NA
NA
NA

No
No
No
No
No
No
No
No
No
No
Yes
Yes
No
Yes
Yes
No
No
No
No
No
Yes
No
Yes
No
No
Yes
No
No
Yes
Yes

8
6
7
6
7
7
4
4
5
2 + 1*
4
4
1
1
5
5
2 + 1*
4
6
7
3
4
4
5
NA
NA
NA
NA
NA
NA

Six cats remained infertile for the duration of the 1 year study
*Resorbed fetus
NA = not applicable

mycobacterial cultures performed on tissue from cat 18
were negative; tissue from cat 8 was not cultured.
Mycobacteria PCR was negative for cat 8 (formalinfixed tissue) and cat 18 (fresh tissue).
Two of the cats with masses did not become pregnant,
and five became pregnant between days 123 and 251. Of
the two cats that developed swelling in their hindlimb
without palpable masses, one did not become pregnant
and the other conceived at day 123. No injection-site reactions were observed in control cats. Tables 2 and 3 detail
injection-site reactions, pregnancy and fetal numbers.

Discussion
This study evaluated the duration of contraception and
safety of a single GonaCon injection in adult female cats
in a simulated free-roaming indoor–outdoor environment. Conditions were as close to a FRC colony as feasible while ensuring a closed population, the ability to
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closely and reliably monitor vaccine response and individual cat health, and the ability to provide veterinary
care as needed. Although vaccinated cats demonstrated
significantly longer time to conception and a reduced
number of fetuses compared with controls, the study
found that a single dose of GonaCon provided contraception lasting for a minimum of 1 year in only 30% (n =
6/20) of treated cats. In a previous study,1 a GnRH-based
vaccine (a previous formulation of GonaCon) induced
fertility control in 100% of treated laboratory cats with a
duration of contraception that varied from 5 months to
>5 years, with a median of nearly 40 months.
The poor contraceptive efficacy of this vaccine vs
prior studies in both female and male cats was not anticipated.1,8,9 Three possibilities have been considered.
One possible explanation could be variability in the
vaccine itself. Although the formulation used in the current study was the same as in the GonaCon safety
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Days are numbered relative to GonaCon injection. Longest dimension of mass: + = <1 cm diameter; ++ = 1–1.9 cm; +++ = 2–2.9 cm; ++++ = 3–3.9 cm; +++++ = 4–4.9 cm; ++++++ = ⩾5 cm;
± = inflammation without palpable mass; A = cat in adoptive home, not assessed

+
A
–
–
–
++
–
–
–
A
A
–
–
–
A
–
–
–
+
+
–
–
–
A
–
–
–
–
–
–
–
–
–
–
–
–
3
8
9
12
15
18
31
36
38

–
–
++++
++
+++++
–
±
++++++
±

–
–
+++
±
–
–
–
+++++
–

–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–

–
++++++
–
–
–
+++++
–
–
–

–
++++
–
–
–
+++
–
–
–

–
+
–
–
–
+++
–
–
–

330–359
270–299
240–269
210–239
180–209
150–179
120–149
90–119
60–89
30–59
Days
0–29
Cat

Table 3 Injection-site reaction (swelling or mass) scores in cats vaccinated intramuscularly with GonaCon
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confirmation study, during which a strong humoral
immune response was measured in all treated cats,3 the
two studies used different batches of vaccine. A retrospective consideration of standard manufacturing
quality-control measures did not offer an explanation for
differences between the two batches, maintenance of
appropriate cold-chain handling was well documented
and the vaccine used in this study did not exceed its
shelf life. A direct comparative analysis between vaccines used in safety confirmation and current studies
was not performed because both batches had expired at
the time of inquiry.
A second potential explanation relates to individual
variability. As with any vaccine, duration of effect is
expected to vary somewhat among individuals.10 Even
when breed, age, source and sex were kept consistent
within previous studies using GnRH-based vaccines,1,8,9
individual cats responded with a variable GnRH antibody production. As increased individual variability
was an essential part of the current study design, an
inconsistent response to vaccination within this population was plausible.
It is noteworthy that individual variability was also
observed in the mating responses of control cats in this
study. Mating and conception was more broadly distributed in the current study than in the Levy et al study,1 in
which all of the sham-treated cats (n = 5) became pregnant 7–28 days after the introduction of the male. In the
current study, 6/10 control cats conceived in a similarly
rapid timeframe, whereas the remaining four control
cats conceived later, 75–119 days after initiation of the
breeding trial.
A third potential explanation stems from plausible differences between laboratory and free-roaming cat populations, including environmental conditions. A consideration
of previous GnRH-based immunocontraceptive studies in
female white-tailed deer reveals a lesser vaccine efficacy in
free-roaming populations of wild deer than in penned,11,12
captive-bred/born populations that received regular veterinary care, housing and a consistent diet.13 However,
results in deer present a difficult analogy because, while
history was not known prior to entering the research facility, cats in this study were normalized to a common plane
of health, nutrition and environment prior to study initiation, and they received regular veterinary care throughout
the study. This precludes equating cats in this study with
the free-roaming wild deer population.
With regard to injection-site reactions, previous studies of cats treated with GonaCon formulations exhibited
reactions similar to those seen in this study.1,3 It is possible that transient reactions in this study went undetected
after the frequency of palpations changed from weekly
to monthly. It is also possible that late-onset reactions
could have developed after cats were removed from the
study and adopted into homes. These findings are
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consistent with the aforementioned safety confirmation
study, in which 4/6 cats developed soft tissue masses at
the site of injection; three of these developed within a
month after injection and one developed 8 months postinjection while in the adoptive home.1,3
Vaccine components that extend duration of response
are believed to contribute to injection-site reactions.14
Although the unpredictable timing, type and severity of
the observed reactions could be perceived as a concern
for field use of this vaccine, none of the reactions observed
in the Levy et al laboratory cats,1 the safety confirmation
study and this field study appeared to cause more than
transient pain or were considered life threatening.3
The goal of testing a temporary contraceptive in this
study was to provide a useful tool in the field to manage
free-roaming cats, as an alternative to surgical sterilization or as an interim tool prior to the availability of a permanent method of non-surgical fertility control.
Simulation modeling using the GonaCon contraceptive
results achieved by Levy et al,1 and using a negative longterm population growth rate as a generic criterion for
population management success, required treating (or
retreating) approximately 50% of the fertile cats in the
population, every 6 months, on a sustained basis. This
was equivalent to a long-term cumulative infertility rate
of 75% of cats. Although it was not explicitly modeled, we
suspect that employing contraception and surgery
sequentially could be logistically advantageous. More
specifically, high initial rates of fertility suppression could
be most quickly achieved by contracepting a large number of cats, with surgery used over a longer subsequent
time period to permanently sterilize contracepted cats
before they revert to fertility.2 Additional research is being
conducted to better characterize the relationship between
contraceptive efficacy and population reduction, including a comparison of the economic requirements of alternative management approaches (J Boone, 2017, personal
communication). This could provide helpful guidance in
designing non-permanent contraception for cats.

Conclusions
A 0.5 ml dose of the GonaCon vaccine formulated and
approved for use in white-tailed deer and wild equid
species did not provide contraception for a sufficient
proportion of female cats housed under colony conditions during this year-long study to justify continuation
of the study or deployment of this immunocontraceptive
for the control of FRC populations.
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